Regavirumab

Modify Date: 2024-01-13 12:29:58

Regavirumab structure	Common Name	Regavirumab
	CAS Number	153101-26-9	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Regavirumab

Regavirumab (MCA C23) is a human monoclonal antibody against cytomegalovirus (CMV), human serum albumin (HSA) and amino acetic acid[1].

Name	Regavirumab

Description	Regavirumab (MCA C23) is a human monoclonal antibody against cytomegalovirus (CMV), human serum albumin (HSA) and amino acetic acid[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> CMV
In Vivo	注射 Regavirumab 后获得的大鼠血清显示出强大的抑制斑块形成的活性[1]。 Regavirumab (2 mg/kg/周，5次)，第4次注射后24 h, Regavirumab 血药浓度达到稳定状态 (74.4±11.8 μg/mL)。末次注射后的消除半衰期与单次注射后相似[1]。
References	[1]. Arizono H, et al. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. Arzneimittelforschung. 1994 Jul;44(7):909-13.

No Any Chemical & Physical Properties